June 1, 2020 / 10:40 AM / a month ago

BRIEF-Antibe Therapeutics Reports Positive Top-Line Data From Study For ATB-346

June 1 (Reuters) - Antibe Therapeutics Inc:

* ANTIBE THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B DOSE-RANGING, EFFICACY STUDY FOR ATB-346

* ANTIBE THERAPEUTICS - ATB-346 DEMONSTRATES SUPERIORITY TO PLACEBO IN REDUCING OSTEOARTHRITIS PAIN

* ANTIBE THERAPEUTICS INC - ATB-346 IS MORE POTENT THAN EXPECTED; LOWEST EFFECTIVE DOSE STILL TO BE ESTABLISHED

* ANTIBE THERAPEUTICS INC - PLANS PIVOTAL PHASE 2/3 ADAPTIVE REGISTRATION TRIAL

* ANTIBE THERAPEUTICS INC - ATB-346, MET PRIMARY ENDPOINT IN PHASE 2B DOSE-RANGING, EFFICACY STUDY

* ANTIBE THERAPEUTICS INC - ATB-346 WAS SAFE AND WELL TOLERATED DURING STUDY

* ANTIBE THERAPEUTICS - THERE WERE VERY FEW SERIOUS ADVERSE EVENTS OR EVENTS LEADING TO WITHDRAWAL OF TREATMENT IN STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below